HGH Fragment 176-191 - Hubio Pharm

Fragment 176-191 is a GH-derived peptide that lacks the ability to bind GH receptors or stimulate IGF-1 production. Nonetheless, it may retain lipolytic effects. Originally synthesized in the 1970s, it was studied briefly before being abandoned. Users report reduced body fat without muscle gain, making it popular in the fitness market. Its biological mechanism is unclear, though it may activate pathways linked to fat metabolism. This fragment is unapproved, not clinically tested in humans, and distributed solely through gray-market channels.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about HGH Fragment 176-191 by Hubio Pharm, consult with your doctor or healthcare professional.